chloromethyl-dimethyl-(4-fluorophenyl)silane | 770-90-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: chloromethyl-dimethyl-(4-fluorophenyl)silane
• 英文别名: (chloromethyl)(4-fluorophenyl)dimethylsilane；chloromethyl(4-fluorophenyl)dimethylsilane；chloromethyl-dimethyl-(4-fluorophenyl)-silane；Chlormethyl-(4-fluor-phenyl)-dimethyl-silan；chloromethyl-(4-fluorophenyl)-dimethylsilane
• CAS: 770-90-1
• 化学式: C₉H₁₂ClFSi
• 分子量: 202.731
• InChiKey: WLPWONBNZDKSEN-UHFFFAOYSA-N

物化性质

• 沸点：
  74-76 °C(Press: 2 Torr)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  chloromethyl-dimethyl-(4-fluorophenyl)silane 在 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 77.0h， 生成 (4-Fluor-phenyl)-jodmethyl-dimethyl-silan
  参考文献：
  名称：

  Structure and polarographic behavior of certain iodomethyltrialkyl(aryl)silanes

  摘要：

  DOI：

  10.1007/bf00844476
• 作为产物：
  描述：

  氯甲基二甲基氯硅烷 、 4-氟苯基溴化镁 以 乙醚 为溶剂， 生成 chloromethyl-dimethyl-(4-fluorophenyl)silane
  参考文献：
  名称：

  Structure and polarographic behavior of certain iodomethyltrialkyl(aryl)silanes

  摘要：

  DOI：

  10.1007/bf00844476

文献信息

• (Aryloxy)methylsilane Derivatives as New Cholesterol Biosynthesis Inhibitors: Synthesis and Hypocholesterolemic Activity of a New Class of Squalene Epoxidase Inhibitors
  作者：Jean-Pierre Gotteland、Isabelle Brunel、Fabrice Gendre、Jerome Desire、Andre Delhon、Didier Junquero、Philippe Oms、Serge Halazy

  DOI：10.1021/jm00017a004

  日期：1995.8

  (aryloxy)silane derivatives of benzylamine (4, 4', or 4") was synthesized and evaluated for hypocholesterolemic activity. Most of the new silane derivatives were identified as potent inhibitors of pig liver squalene epoxidase with IC50 values in the submicromolar range. In vitro inhibition of cholesterol biosynthesis in Hep-G2 cells was observed with a very good potency for the ene-yne derivatives 4a, 4i,

  合成了一系列苄胺的3-取代的（芳氧基）硅烷衍生物（4、4'或4”），并评估了其降胆固醇活性。大多数新的硅烷衍生物被鉴定为有效的猪肝角鲨烯环氧酶抑制剂，IC50值为在亚微摩尔范围内。对于烯-炔衍生物4a，4i，4n，4q和4u以及炔-炔化合物4“，体外观察到的Hep-G2细胞中胆固醇生物合成的抑制作用非常好。 。在体内，发现4i，4u，4'和4“口服后ED50值在2-7 mg / kg范围内时，会降低大鼠体内的胆固醇生物合成。因此，这些新的苄胺的（芳氧基）甲基硅烷衍生物代表一类新的强力角鲨烯环氧酶抑制剂，具有降低胆固醇的特性。
• Organic compounds
  申请人：Bayer Aktiengesellschaft

  公开号：US06313344B1

  公开（公告）日：2001-11-06

  Compounds of formula (I), wherein either X is CH or N, Y is OR1 and Z is O, or X is N, Y is NHR8 and Z is O, S or S(═O); R1, R2 and R3 are as defined according to the specification; m is 0, 1 or 2; R5 is, for example, halogen, C1-C6alkyl, halo-C1-C6alkyl or C3-C6cycloalkyl; n is 0, 1, 2, 3 or 4; R9 is methyl, fluoromethyl or difluoromethyl; A and R7 are as defined according to the specification; D is O, S, —S(═O) or S(═O)2; G is C1-C6aalkylene; T—R6 is R6, —C(═N—O—A1—R77)—R6; —SiR14(R15)—R6; —C(═O)—R6; —C(R16)═C(R17)—R6, —C≡C—R6 or —D—R6; R6 is C1-C4alkyl or unsubstituted or substituted aryl or heteroaryl; A1 and R77 are as defined above for A and R7; L is U—R18, P(OR)vR11R12, P(S)wR11R12 or N(aryl)R13; v and w are 0 or 1; U—R18 is —C(═O)—C(═O)—R18; —C(OH)—C(OH)—R18; —C(═N—O—A1—R7)—R18; a is 0 or 1; b is 0 or 1; R11, R12 and R13 are, for example, C1-C6alkyl, halo-C1-C6alkyl or C3-C6cycloalkyl; R14 and R15 are each independently of the other C1-C4alkyl; R16 and R17 are each independently of the other hydrogen, C1-C4alkyl or halogen and R18 is R5; and, where applicable, their possible E/Z isomers, mixtures of E/Z isomers and/or tautomers, in each case in free form or in salt form, a method of controlling pests, a process for the preparation of those compounds and their use are described.

  式（I）的化合物，其中X为CH或N，Y为OR1，Z为O，或X为N，Y为NHR8，Z为O，S或S（═O）；R1、R2和R3如规范中所定义；m为0、1或2；R5为例如卤素、C1-C6烷基、卤代C1-C6烷基或C3-C6环烷基；n为0、1、2、3或4；R9为甲基、氟甲基或二氟甲基；A和R7如规范中所定义；D为O、S、—S(═O)或S(═O)2；G为C1-C6烷基；T—R6为R6、—C(═N—O—A1—R77)—R6；—SiR14(R15)—R6；—C(═O)—R6；—C(R16)═C(R17)—R6、—C≡C—R6或—D—R6；R6为C1-C4烷基或未取代或取代的芳基或杂环烷基；A1和R77如上述A和R7所定义；L为U—R18、P(OR)vR11R12、P(S)wR11R12或N(芳基)R13；v和w为0或1；U—R18为—C(═O)—C(═O)—R18；—C(OH)—C(OH)—R18；—C(═N—O—A1—R7)—R18；a为0或1；b为0或1；R11、R12和R13为例如C1-C6烷基、卤代C1-C6烷基或C3-C6环烷基；R14和R15各自独立地为C1-C4烷基；R16和R17各自独立地为氢、C1-C4烷基或卤素，R18为R5；以及在游离形式或盐形式中，所述E/Z异构体、E/Z异构体混合物和/或互变异构体的可能性及其使用方法的控制害虫的方法，制备这些化合物的过程以及它们的用途。
• Fungicidal (1H-1,2,4-triazolyl)disilaalkanes
  申请人：Korea Institute of Science and Technology

  公开号：US05235061A1

  公开（公告）日：1993-08-10

  This invention relates to (1H-1,2,4-triazolyl)disilaalkanes as represented by formula I, their preparation, and their use in controlling fungus diseases of living plants. ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 can be independently lower alkyl, vinyl, allyl, benzyl, or substituted phenyl such as para-fluorophenyl, para-chlorophenyl, para-enthoxyphenyl, and biphenyl.

  该发明涉及以式I所代表的(1H-1,2,4-三唑基)二硅烷烷的制备及其在控制植物真菌病中的应用。其中R₁、R₂、R₃、R₄和R₅可以独立地是较低的烷基、乙烯基、烯丙基、苄基或取代苯基，如对-氟苯基、对-氯苯基、对-乙氧基苯基和联苯基。
• Pharmaceutical compositions containing therapeutically active organosilane derivatives and process for preparing same
  申请人：Richter Gedeon Vegyészeti Gyár R.T.

  公开号：EP0472304A3

  公开（公告）日：1992-04-22

  The invention relates to pharmaceutical compositions containing an active ingredient at least one known organosilane derviative of formula (I), wherein R1 represents a hydrogen or halogen atom ;A represents oxygen or =CH2 or NR group, wherein R represents a hydrogen atom or a C1-4alkyl group ;m is 1, 2 or 3; andn is 1 or 2, or a pharmaceutically acceptable salt thereof in admixture with one or more pharmaceutically acceptable carriers, excipients and/or diluents.The compositions of the invention possess muscle relaxant and antiparkinsonic effects, thus, they can be used for the treatment or prevention of diseases and conditions accompanied by hyperreflexia of the central nervous system and/or an increase of the muscular tone as well as nervous system injuries, degenerative nervous system disoders, sclerosis multiplex, myelopathies, rachicele, articular pains and Parkinson's disease in mammals including man.

  该发明涉及含有至少一种已知的有机硅衍生物的活性成分的药物组合物，其化学式为(I)，其中R1代表氢或卤原子；A代表氧或=CH2或NR基团，其中R代表氢原子或C1-4烷基基团；m为1、2或3；n为1或2，或其在与一个或多个药学上可接受的载体、赋形剂和/或稀释剂的混合物中的药学上可接受的盐。该发明的组合物具有肌肉松弛和抗帕金森效应，因此，它们可用于治疗或预防伴有中枢神经系统高反射和/或肌肉张力增加以及神经系统损伤、退行性神经系统疾病、多发性硬化、脊髓病、关节疼痛和帕金森病等疾病和症状的哺乳动物，包括人类。
• MOBERG, W. K.
  作者：MOBERG, W. K.

  DOI：——

  日期：——